Transforming growth factor beta 1 (TGF-b1) is the most potent inhibitor of myogenic differentiation (MyoD) of rhabdomyosarcoma (RMS); however, the underlying mechanisms of this inhibition remain unclear. In this study, we identified novel TGF-b1-related microRNAs (miRNAs); among these, miR-450b-5p is significantly regulated by TGF-b1. We provide evidence that TGF-b1 exerts it function by suppressing miR-450b-5p. Both in cultured cells and tumor implants, miR-450b-5p significantly arrested the growth of RMS and promoted its MyoD. Utilizing a bioinformatics approach, we identified miR-450b-5p target mRNAs. Among these candidates, only the expression of ecto-NOX disulfide-thiol exchanger 2 (ENOX2) and paired box 9 (PAX9) was augmented by miR450b-5p knockdown examined by western blot; the engineered inhibition antagonized TGF-b1-mediated differentiation inhibition. Furthermore, we found that the Smad3 and Smad4 pathways, but not Smad2, are the principal mediator of TGF-b1 suppression of miR-450b-5p. Taken together, these results suggest that disrupting the TGF-b1 suppression of miR-450b-5p, or knockdown of ENOX2 and PAX9, are effective approaches in inducing RMS MyoD.
INTRODUCTION
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in pediatric patients and young adults. The two major histological types of RMS tumors are alveolar RMS (ARMS) and embryonal RMS (ERMS). Although most RMS is characterized by expression of myogenic-promoting transcription factors, such as myogenic differentiation (MyoD) and myogenin, there is failure of terminal muscle differentiation.
1,2 Therefore, strategies aimed at storing the myogenic program and reverse RMS cell-malignant behavior could potentially aid in therapeutic intervention. Recent evidence has demonstrated the role of microRNAs (miRNAs) in the development and progression of RMS. Several reports have shown that the expression of miR-1 and miR-133a is markedly decreased in RMS cell lines compared with differentiated myoblasts and skeletal muscle tissues. In particular, re-expression of miR-1 or miR-206 restores the MyoD programs of RMS cells and blocks the tumorigenic phenotype in vivo, raising the possibility that miRNA re-expression potentially represents an effective differentiation therapy for RMS. 3 However, miRNA therapy presents several challenges, 4, 5 such as delivery limitations, instability and side effects. In particular, miRNA re-expression influences the expression of hundreds of genes involved in cellular pathways and exhibits potentially unpredictable side effects. Thus, a more detailed understanding of the molecular events governing myogenesis is warranted to identify the myogenesis-related miRNA biogenesis, and modulation in which cellular pathways participate.
Transforming growth factor beta 1 (TGF-b1) is known to be a critical modulator of skeletal muscle differentiation. 6, 7 Our previous report revealed that inhibition of TGF-b1 signaling in human RMS cell line, RD, promotes tumor cell MyoD, [8] [9] [10] but the underlying mechanism remains unclear. In recent years, several reports have shown that TGF-b1 signaling promotes the metastasis and invasive potential of cancer cells through the modulation of biosynthesis of oncogenic miRNAs such as miR-21, 11 miR-155 12 and miR-181b. 13 Moreover, reports have demonstrated that TGF-b1 signaling also has an important role in skeletal muscle differentiation via regulation of miR-24; 7 a recent report demonstrated that TGF-b regulates miR-206 and miR-29 to control MyoD of the C2C12 cell line. These findings revealed a newly discovered mechanism in the TGFb1 autocrine/paracrine pathway concerning the development of malignancy; thus, there is a need for further elucidation of TGF-b1-regulated miRNAs that have critical roles in the regulation of RMS.
To investigate the role of TGF-b1-regulated miRNAs in the progression of RMS, we performed comprehensive miRNA microarray analysis on RNA derived from typical RMS cell lines and TGF-b1 knockdown cell lines. We identified a novel set of TGFb1-related miRNAs that included miR-450b-5p, one of the most significantly expressed miRNAs; we confirmed this finding in RMS tissues. As we were interested in determining whether these miRNAs could potentially contribute to TGF-b1-mediated differential inhibition, we performed sequence complementary analysis of these miRNAs against proliferation or myogenic regulators; our findings revealed that only induction of miR-450b-5p conferred MyoD in RMS cells. In this study, we provide evidence that ecto-NOX disulfide-thiol exchanger 2 (ENOX2) and paired box 9 (PAX9) are targets of miR-450b-5p, and we show that ENOX2 and PAX9 mRNAs and miR-450b-5p are inversely expressed in human RMS tissues. Moreover, our findings indicate that miR-450b-5p is negatively regulated by Smad4 and Smad3 in addition to TGF-b1, and that restoration of miR-450b-5p occurs via RNA interference of these genes.
RESULTS

TGF-b1 regulates miRNA in human RMS cell lines
To identify TGF-b1-related miRNAs, we conducted comprehensive locked nucleic acid microarray analyses to obtain miRNA expression profiles independently in TGF-b1 knockdown cell lines (RD, SMS-CTR and RH28) and control cell lines. Figure 1a displays statistically significant expression changes of the miRNAs in these representative RMS cells (fold change X1.5, Pp0.05). The five miRNAs with overexpression levels in TGF-b1 knockdown RMS cell lines were: miR-4275, miR-411, miR-493* and miR-450b-5p. Only miR-2113 expression was significantly downregulated in TGF-b1 knockdown RMS cell lines versus controls. Raw microarray data are accessible through Gene Expression Omnibus Series accession number GSE40843.
To validate the expression profiles of these miRNAs independently, we conducted real-time RT-PCR assays using total RNA isolated from TGF-b1 knockdown RMS cell lines (ERMS: RD, RH36 and SMS-CTR; ARMS: RH30, RH28 and RH3) and control cells. Of interest, nearly all the TGF-b1 knockdown RMS cell lines overexpressed miR-450b-5p (4/6) ( Figure 1b) . Among other identified miRNAs by microarray analyses, miR-411-5p, miR-411-3p and miR-493-5p were significantly upregulated (Po0.05) in RNA derived from TGF-b1 knockdown RMS cell lines (see Supplementary  Information, Supplementary Figure S1 ).
TGF-b1 and miR-450b-5p exhibited a correlation in human RMS tissues The above work demonstrated that differential expression of miRNAs in TGF-b1-knocked down RMS cell lines versus controls, thus, we hypothesized that the augmented miRNAs identified in TGF-b1 knocked down RMS cells would also be overexpressed in TGF-b1-low-expression RMS tissues compared with TGF-b1-highexpression RMS tissues. To explore this possibility, we examined these miRNAs by real-time RT-PCR using total RNA isolated from paired human RMS tissues that exhibited low-high expression of TGF-b1. Based on the 68 cases of RMS that we previously described 9 and 12 cases collected recently, the immunohistochemical-staining findings for TGF-b1 revealed that 54 of the 80 cases of RMS tissues exhibited TGF-b1-high expression (see Supplementary Information, Supplementary Table S1). Among these miRNAs, miR-450b-5p exhibited the most significant increase in expression (3.2-fold) in TGF-b1-low-expression RMS tissues (Figure 2a ), and these findings were confirmed by northern blot and RT-PCR analysis independently (Figure 2b ). In addition, we explored another six paired human RMS tissues having lowhigh expression of TGF-b1, with RT-PCR and our findings revealing that the majority (4/6) of TGF-b1 low-RMS tissues exhibited higher miR-450b-5p expression compared with TGF-b1 high-RMS tissues (Figure 2c ). In contrast, the other miRNAs that were identified as differentially overexpressed in TGF-b1-knocked down RMS cells (shown in Figure 1 ) were identified as being overexpressed in only a minority of TGF-b1-low RMS tissues (data not shown). Of these TGF-b1-deregulated miRNAs, our findings suggested that miR450b-5p acted as an important regulator, and thus was selected for further study.
MiR-450b-5p arrests proliferation of RMS by inducing apoptosis In order to investigate whether TGF-b1-related miRNAs were responsible for RMS proliferation, we transiently transfected mimics and inhibitors of these miRNAs into RD (ERMS) and RH28 (ARMS) cells in vitro (Figure 3 ). Over 90% of cells from each cell line were transfected (data not shown), and expression of transfected miRNAs was confirmed by real-time RT-PCR analysis ( Figure 3A ). Our findings revealed that [ 3 H] thymidine incorporation of RMS cells transfected with miR-450b-5p mimic was reduced ( Figure 3B ). Similar results were found in optical density, as demonstrated by a time-dependent decrease in [ 3 H] thymidine incorporation. Significant differences in proliferation were observed after 4 (Po0.05) and 6 (Po0.01) days. No significant differences in proliferation were found for other miRNAs, such as miR-4275, miR-493-5p and miR-493-3p, or control transfectants (data not shown). Next, to determine whether growth arrest was a consequence of RMS cell apoptosis, we utilized caspase-3 and TUNEL (terminal deoxynucleotidyl transferase dUTP nick end labeling). As expected, the number of caspase-3-and TUNELpositive cells increased significantly after 4 days of miR-450b-5p mimic transfection. Notably, the apoptosis induced with miR450b-5p mimic was enhanced by TGF-b1 small interfering RNA (siRNA) treatment ( Figure 3C ). Apoptosis is closely related to tumor cell differentiation and progression; 14 thus, this suggests that miR450b-5p is an anti-oncogene miRNA. MiR-450b-5p represses tumorigenicity in vivo by promoting MyoD To further examine whether the observed growth arrest of RMS in vitro was associated with repression in vivo, we quantified tumorigenicity using an in vivo nude mouse animal model. Two weeks after tumor cell inoculation, all nude mice developed detectable tumors that reached B0.5 cm 3 . Next, tumors were injected with mimic, inhibitors of miR-450b-5p and negative control oligonucleotides in transfection solution (see Materials and methods) once weekly for 4 weeks. There was a significant difference between the mimic-treated group and control group after 3 weeks (Po0.01), and after 4 weeks the significant difference was even greater (Po0.005) ( Figure 4A ). This finding suggests that miR-450b-5p mimic inhibits the tumorigenicity of RD cells; this was further confirmed by Ki67 expression ( Figure 4B , Po0.05).
It is well understood that the biological behavior of a tumor is related to the degree of differentiation of its cells, and a lower degree of differentiation generally correlates with greater tumor growth. As miR-450b-5p arrests in vitro growth and in vivo tumorigenicity of RMS, we examined the role of miR-450b-5p in differentiation of RD cells. As shown in Supplementary Information, (Supplementary Figure S2) , after tumors were treated with miR-450b-5p mimic once weekly for 2 weeks, tumor cells exhibited typical ultrastructural features of MyoD: convoluted nucleus and an increase in organelles, degeneration of nucleus and cytoplasm, and increased myofilament. The tumor cell control group typically contained a single nucleolus and few organelles, with no obvious evidence of MyoD (data not shown). Moreover, miR-450b-5p mimic induced an increase in staining for myogenin (Po0.01) and myosin (Po0.05) ( Figures 4B and C) ; this was further confirmed by real-time RT-PCR analysis. As shown in Figure 4D , there was a significant difference in the ratio of myogenin mRNA/GAPDH (Po0.005) and myosin mRNA/GAPDH (Po0.005) between the miR-450b-5p mimictreated group and control groups. In a parallel experiment, we investigated antagonistic effect of TGF-b1 on miR-450b-5p mimicinduced RMS cell MyoD. As anticipated, TGF-b1 counteracted the expression of myogenin and myosin, and the differentiationinducing effect of miR-450b-5p mimic on RMS tissues. ENOX2 and PAX9 are direct targets of miR-450b-5p Six of the predicted miR-450b-5p targets overlapped between the three bioinformatic algorithms, including calcium/calmodulindependent protein kinase II inhibitor 1, microtubule-associated protein 2, ankyrin 3, ENOX2, PAX9 and ATPase, class VI, type 11C. Among these candidates, only ENOX2 and PAX9 were repressed by induced miR-450b-5p overexpression and augmented by its engineered knockdown in RMS cells, as examined by RT-PCR Table S1) . Bars indicate RNA level normalized to GAPDH ± s.d. MiR-450b-5p level in RMS with low versus high TGF-b1 expression. Each assay was conducted for at least three independent times. *Po0.05; **Po0.01.
TGF-b1 suppression of miRNA-450b-5p expression MM Sun et al ( Figure 5a ). All six cell lines (ERMS: RD, RH36 and SMS-CTR; ARMS: RH30, RH28 and RH3) were independently examined in these analyses, and yielded concordant results. Next, we confirmed the effects of miR-450b-5p-mimic/inhibitor on the protein levels of ENOX2/PAX9 in RD cells. As shown in Figure 5b , downregulated protein levels of ENOX2 and PAX9 were determined in RD cells 24 h following miR-450b-5p-mimic treatment. However, higher protein levels of ENOX2 and PAX9 were found in RD cells treated with miR-450b-5p-inhibitor; in addition, there was a more significant increase in PAX9 (Po0.05).
To confirm the effects of TGF-b1 treatment on the expression of miR-450b-5p, ENOX2 and PAX9 in the RD cell line relative to TGF-b1 knockdown, we investigated the mRNA levels of miR450b-5p, ENOX2 and PAX9 in RD cells treated with 5 or 10 ng/ml TGF-b1, compared with TGF-b1-knocked down RD cells. As shown in Figure 5c , miR-450b-5p was increased in TGF-b1-knocked down RD cells, but decreased in TGF-b1-treated RD cells, particularly in the 10-ng/ml TGF-b1 treatment group. Both ENOX2 and PAX9 expression in TGF-b1-knocked down RD cells was decreased. However, TGF-b1 treatment led to a slight increase of ENOX2 in RD cells and a marked increase of PAX9.
Next, we explored whether the 3 0 -untranslated repeat (UTR) of ENOX2 and PAX9 are functional targets of miR-450b-5p. As shown in Figure 5d , the reporter activities for wild-type 3 0 -UTR sequences TGF-b1 suppression of miRNA-450b-5p expression MM Sun et al of both ENOX2 and PAX9 were decreased by co-transfection with miR-450b-5p mimic in RD cells and increased by co-transfection with miR-450b-5p inhibitors. However, the activity of report construct mutated at the specific miR-450b-5p target site was unaffected by simultaneous transfection. To comprehensively explore the clinical association between TGF-b1, miR-450b-5p, and targets ENOX2 and PAX9, we examined mRNA isolated from human RMS tissues with low-high expression of TGF-b1. According to our previously optimized scoring system of TGF-b1 expression in paraffin-embedded tissues of RMS, 9 we paired TGF-b1-low-expression (immunoreactive score 0-4) RMS tissue with TGF-b1-high-expression (immunoreactive score 6-9) RMS tissue. As shown in Figure 5e , high ENOX2 and PAX9 expression levels were associated with low miR-450b-5p expression and high TGF-b1 expression. The statistical analysis demonstrated that miR-450b-5p was significantly expressed in the majority of paired tissues (4/6), ENOX2 was significantly expressed in half of the paired tissues (3/6) and ENOX2 was significantly expressed in more than half of the paired tissues (4/6). These results are in concordance with findings obtained in RMS cell lines. TGF-b1 suppression of miRNA-450b-5p expression MM Sun et al MiR-450b-5p downregulates ENOX2 and PAX9 proteins, and promotes MyoD of RMS We examined the mRNA levels of ENOX2 and PAX9 in siRNAmediated ENOX2 or PAX9-knocked down RD cells, respectively, 48 h after initial miR-450b-5p-mimic transfection to determine whether the effects of miR-450b-5p would be enhanced. As shown in Figure 6A , ENOX2-targeting siRNAs and PAX9-targeting siRNAs each repressed the respective mRNAs to 0.17-and 0.33-fold change/GAPDH, compared with 1.93-and 1.83-fold change/GAPDH in the control. As anticipated, miR-450b-5p mimic TGF-b1 suppression of miRNA-450b-5p expression MM Sun et al intensified the effects of ENOX2 siRNA and PAX9 siRNA knockdown on mRNA levels of ENOX2 and PAX9. Next, to study whether ENOX2 and PAX9 were involved in miR-450b-5p deregulation and mediated the block of RMS MyoD, we individually knocked down these target genes using siRNAs in RD cells, and the number of caspase-3 and myosin heavy chain (MHC)-positive cells was analyzed using rabbit anti-caspase-3 and MHC. As shown in Figure 6B , siRNA-mediated knockdown of either ENOX2 or PAX9 induced apoptosis and MyoD, as well as miR-450b-5p mimic. Furthermore, we observed that siRNA-mediated knockdown of either ENOX2 or PAX9 promoted apoptosis and MyoD caused by engineered miR-450b-5p derepression ( Figure 6C ). Similar assays were conducted with RH28 cells and similar results were independently obtained (see Supplementary Information,  Supplementary Figure S3 ).
TGF-b1 signal pathway regulates miR-450b-5p To investigate whether the downstream proteins of the TGF-b1 signal pathway have a key role in the regulation of miR-450b-5p and ENOX2/PAX9, we examined the expression levels of miR450b-5p and ENOX2/PAX9 in TGF-b1-, Smad4-, Smad2-and Smad3-knocked down RMS cell lines. To determine whether these signal proteins exhibited complete knockdown, we examined Smad7, a TGF-b1-inducible antagonist of TGF-b1 signaling in TGFb1 signal-gene-knocked down RD and RH28 cells treated with TGF-b1 5 ng/ml. As shown in the Supplementary Information, Supplementary Figure S4 , Smad7 expression increased significantly in the TGF-b-treated TGF-b1-knocked down group, and not in Smad4-, Smad2-and Smad3-knocked down RMS cell lines. We observed greater expression of pre-miR-450b-5p and mature-miR-450b-5p in TGF-b1 siRNA-treated RD cells and RH28 cells compared with controls (Figure 7a) . Moreover, the signal of ENOX2 and PAX9 was decreased in TGF-b1-, Smad4-and Smad3-knocked down RD cells, but not in Smad2-knocked down RD cells examined with ENOX2-and PAX9-3 0 -UTR-containing reporter ( Figure 7b) ; a similar finding was observed in RH28 cells ( Supplementary Information, Supplementary Figure S5) . These results suggest that a key role is played by Smad4/3 on miR-450b-5p/ENOX2/PAX9 regulation.
As miR-450b-5p is in a miRNA cluster with miR-450a/b-3p/b-5p, and TGF-b1 regulates miR-450b-5p, it may also regulate other miRNA clusters. To test this hypothesis, we examined miR-450a, miR-450b-5p and miR-450b-3p in TGF-b1 signal-protein genesilenced RD cells individually. As shown in Figure 7c , miR-450a, miR-450b-5p and miR-450b-3p expression was more or less induced in TGF-b1 signal-protein gene-silenced RD cells. Interestingly, exogenous TGF-b1 antagonized miR-450b-5p and miR-450b-3p levels in TGF-b1-and Smad2-knocked down RD cells, but not in Smad4-and Smad3-knocked down RD cells. These findings revealed that Smad3, not Smad2, has an important role in control processing of miR-450b-5p expression, as well as the common Smad and Smad4. This observation provides additional evidence that TGF-b1 inhibits muscle differentiation through Smad3. 15 
DISCUSSION
The TGF-b1 signaling pathway has a vital role in the development and homeostasis of normal tissues, and abnormal function of this pathway contributes to the initiation and progression of diverse cancer types, including RMS. 9, 16, 17 Our results demonstrated that miR-450b-5p acts as a tumor suppressor, has a key role in MyoD of RMS by targeting of ENOX2 and PAX9, and is negatively regulated by the TGF-b1/Smad pathway.
Previous studies have shown that TGF-b1 regulates the expression of several miRNAs. These studies suggest that these TGF-b1-upregulated miRNAs function as oncogenes; miR-21 targets programmed cell death 4, 11 miR-155 contributes to epithelial cell plasticity by targeting RhoA, 12 and miR-181b targets the tissue inhibitor of metalloprotease 3. 13 In this study, we performed a genome-wide analysis of differentially expressed miRNAs in TGF-b1-knocked down or not RMS cell lines, and identified TGF-b1-related miRNAs in RMS for the first time. We demonstrated that a set of miRNAs was prominently upregulated in TGF-b1-knocked down RMS cells.
In recent years, miRNAs have emerged as prominent factors in cancer. With respect to cancer, miRNAs are often located in unstable genomic regions, and therefore are typically downregulated in tumors; 18 moreover, inhibition of miRNA biogenesis tends to enchance tumorigenesis. 19 Several studies have demonstrated that miRNA maturation pathways crosstalk with intracellular signaling molecules, Smad proteins, 11 estrogen receptor 20 and p53. 21, 22 To determine whether TGF-b1 downregulates miR-450b-5p as a tumor suppressor or not, we engineered re-expression of miR-450b-5p-repressed proliferation of both ERMAS cell line RD and ARMS cell line RH28; however, modest or no significant growth inhibition was observed in miR-450b-5p inhibitor-treated RMS cell lines (Figure 3) . Engineered re-expression of miR-450b-5p also reduced in vivo tumorigenicity. Notably, this repression of in vivo tumorigenicity depended on time-dependent treatment of miR-450b-5p mimic ( Figure 4) .
As miR-450b-5p arrests the growth of RMS, we examined the role of miR-450b-5p in the differentiation of RD cells. We investigated apoptosis (caspase-3 and TUNEL), MyoD regulator (myogenin), makers of MyoD (myosin and desmin) and morphology changes in RD cells treated with miR-450b-5p mimic in vitro and in vivo. These findings revealed that miR-450b-5p promotes MyoD of RMS cells by inducing apoptosis, which suggests that miR-450b-5p is a tumor suppressor. Western blot confirmed the effects of miR-450b-5p mimic/inhibitor on the protein levels of ENOX2/PAX9 in RD cells. Downregulated protein levels of ENOX2 and PAX9 were explored in RD cells 24 h after being treated with miR-450b-5p mimic. However, the higher protein levels of ENOX2 and PAX9 were explored in RD cells 24 h after being treated with miR-450b-5p inhibitor, and PAX9 increased more significantly (Po0.05). (c) RT-PCR confirmed the effects of TGF-b1 treatment on the expression of miR-450b-5p, ENOX2 and PAX9 in RD cell line, relative to TGF-b1 knockdown. MiR-450b-5p increased in TGF-b1-knocked down RD cells, but decreased in TGF-b1-treated RD, especially more significantly in 10 ng/ml TGF-b1 treatment. Both ENOX2 and PAX9 in TGF-b1-knocked down RD cells decreased. The TGF-b1 treatment leads to a slight increase of ENOX2, but a marked increase of PAX9. (d) Diagram of ENOX2-and PAX9-3 0 -UTR-containing reporter constructs RD with transfection of Wt-or mut-report and miR-450b-5p mimic or inhibitor (miR-M or miR-I). The luciferase assays confirmed that miR-450b-5p binds to the wild-type 3 0 -UTR sequences of ENOX2 and PAX9 in RD cells. Co-transfection of miR-450b-5p mimic significantly reduced the luciferase levels, and co-transfection of miR-450b-5p inhibitor increased luciferase levels. Mut: contains seven-base mutation at the miR-450b-5p target region. (e) Clinical association between TGF-b1, miR-450b-5p, and targets ENOX2 and PAX9 were examined by real-time PCR. 235, 458, 1123, 2879, 5627, 9876 versus 154, 2354, 63222, 7789, 14567, 11526, respectively (the Arabic numerals are numbers of RMA tissues). Each assay (a-c) was conducted at least three independent times. Error bars indicate s.d. *Po0.05; **Po0.01; ***Po0.005.
We identified six miR-450b-5p targets, including ENOX2 and PAX9 by bioinformatic analyses, and functional as well as binding assays. It is known that each miRNA can affect multiple targets via distinct mechanisms. 23 Thus, we focused on identification of candidate miR-450b-5p targets that could exert a miR-450b-5p growth inhibition-or differentiation-inducing effect. The mRNAs of ENOX2 and PAX9 were downregulated in RMS cell lines treated with miR-450b-5p-mimic, and induced differentiation with increased numbers of TUNEL-positive cells and myogenic marker MHC-positive cells, reinforced by siRNA-mediated knockdown of either ENOX2 or PAX9 ( Figure 6 ). Our investigation of clinical associations demonstrated that there is an inverse relationship between miR-450b-5p and targets, ENOX2 and PAX9, and a similar inverse relationship between miR-450b-5p
and TGF-b1 expression in RMS tissues. Taken together, these findings are in concordance with previous reports that TGF-b1 signal pathways contribute to the inhibition of differentiation in RMS 9 by revealing specific miRNAs that are underexpressed in RMS. We propose that miR-450b-5p acts as an antioncomir in this context by negatively regulating specific oncogenes. This view is supported by miR-450b-5p re-expression or knockdown experiments, in which its targets ENOX2 and PAX9 exhibited derepression or repression, respectively. Thus, the TGF-b1/miR450b-5p/ENOX2/PAX9 pathway constitutes a previously unrecognized differentiation regulator of RMS. It is unclear how ENOX2 and PAX9 are involved in the MyoD of RMS. Based on our finding that miR-450b-5p mimic induces apoptosis and differentiation, which is reinforced by knockdown of either TGF-b1 suppression of miRNA-450b-5p expression MM Sun et al ENOX2 or PAX9 (Figure 6 ), and previous reports demonstrating that ENOX2 enhances cell proliferation and PAX9 modulates tissue differentiation, [24] [25] [26] we hypothesized that these interactions caused RD cells to drop out of cell cycle and block MyoD in RMS cells; further studies are warranted to investigate this hypothesis.
Recently, several studies have demonstrated that the expression of specific miRNAs that regulate skeletal muscle development have been shown to be downregulated in RMS, raising the possibility that miRNA re-expression could potentially serve as an effective differentiation therapy for RMS. RMS most commonly originates from skeletal muscle; however, a recent finding indicates that RMS also originates from adipocyte lineage, 27 indicating that the complex origination is far beyond our present understanding. Therefore, exploration of differentially expressed miRNAs between RMS and muscle tissue is warranted. We determined the differentially expressed miRNAs in a number of representative TGF-b1-knocked down ERMS and ARMS cell lines, based on the common biological behavior, the excretive TGF-b1, differentiation block and coloration, previously demonstrated by our reports and other reports. Whether or not there are differentiated miRNAs between ERMS and ARMS, and associations between ERMS/ARMS and TGF-b1/miR-450b/ENOX2/ PAX9 axis, requires further study.
Several TGF-b1-regulated miRNAs have been shown to mediate TGF-b1 signaling to control the aggressiveness of cancer cells associated with metastasis and invasiveness. [11] [12] [13] In this study, of the six significantly differentially expressed miRNAs, none of the Figure 7 . Smads-mediated TGF-b1 signal pathway regulates miR-450b-5p. (a) Real-time RT-PCR analysis on the effect of TGF-b1 siRNA on miR450b-5p processing in RMS cell lines. The level of pre-miR-450b-5p and mature miR-450-5p increased in RD and RH28 cells treated with TGF-b1 siRNA for a period of 6 days; moreover, mature miR-450-5p exhibited a more marked increase compared with pre-miR-450b-5p. Ctrl means the control for mature miR-450-5p in RD and RH28 cells treated with TGF-b1 siRNA for a period of 24 h. (b) The luciferase assay analysis of miR450b-5p targets ENOX2 and PAX9. The luciferase reporter confirmed that miR-450b-5p binds to the wild-type 3 0 -UTR sequences of ENOX2 and PAX9 in RD cells ( Figure 5 ). Signals of ENOX2 and PAX9 in TGF-b1-, Smad4-, Smad2-and Smad3-knocked down RD were examined after 48 h in differentiation medium. Each assay was conducted at least three independent times. (c) Real-time RT-PCR analysis on expression of miR-450a, miR-450b-5p and miR-450b-3p in TGF-b1-, Smad4-and Smad3-knocked down RD cells treated with exogenous TGF-b1 5 ng/ml. Methods for TGF-b1-, Smad4-, Samd2-and Smad3-knocked down RD construction see Materials and methods, and Supplementary Information, Supplementary Figure S4 . Error bars indicate s.d. *Po0.05; **Po0.01; ***Po0.005. (d) Schematic illustration of miR-450b-5p processing via TGF-b1 signal pathway, block of RMS differentiation, miR-450b-5p targets ENOX2 and PAX9, and their possible relationship.
TGF-b1 suppression of miRNA-450b-5p expression MM Sun et al miRNAs exhibited a change consistent with these results. This discrepancy may be due to the use of different cell types and interference means to TGF-b1 signal for the miRNA array analysis. However, an important inconsistency between TGF-b1-mediated upregulation of these miRNAs, such as miR-21, 11 miR-181 13 and miR-155 expression, 12 and TGF-b1-mediated downregulation of miR-450b-5p is the requirement of the common Smad, Smad4 (Figure 7) . Moreover, we demonstrated that Smad3 has an important role in control processing of miR-450b-5p expression, as well as Smad4. Consistent with this finding, a previous study reported that TGF-b1 inhibited muscle differentiation through the Smad3-mediated repression of myogenic transcription factors. 15, 28, 29 Further investigation is required to determine the mechanism underlying the TGF-b1/Smad pathway downregulation of miR-450b-5p, although it is likely that the regulation occurs post transcriptionally (Figure 7d) .
This study revealed a novel mechanism for blocking MyoD of RMS, that is, TGF-b1 suppression of miRNA-450b-5p expression. Engineered re-expression of miR-450b-5p arrested growth of RMS and promoted MyoD of RMS in vitro and in vivo. Notably, ENOX2 and PAX9 were targeted by miR-450b-5p, providing a likely mechanism responsible for the blocking of TGF-b1-mediated RMS differentiation through previously unrecognized regulation of tumor-promoting pathways. It is intriguing to speculate that use of miR-450b-5p as a differentiation therapy for RMS could potentially provide even prognostic information. Indeed, evidence indicates that clinical associations exist between miR-450b-5p and the histological grade of RMS differentiation (data not shown), and miR-450b-5p mimic promotes RMS differentiation in vitro and in vivo. Taken together, these findings indicate that miR-450b-5p acts as an anti-oncogenic miRNA in RMS by conferring repression of specific oncogenes. Conceivably, targeting of miR-450b-5p by anti-miR oligonucleotides would constitute a novel approach to arrest RMS development.
MATERIALS AND METHODS
Cell culture and RMS tissue sampling
The human ERMS (RD, RH36 and SMS-CTR) and ARMS (RH30, RH28 and RH3) cell lines were obtained from the American Type Culture Collection (ATCC; Manassas, VA, USA) and were maintained in Dulbecco's modified Eagle's medium. The differentiation medium comprised serum-free Dulbecco's modified Eagle's medium with 10 mg/ml insulin and transferrin. 30, 31 All samples were obtained following informed consent and with obscured identity corroding to the recommendations of the Institutional Review Board. The histological material consisted of initial biopsy or resection specimens and of post-chemotherapy biopsy specimens from residual, recurrent or metastatic tumor sites.
Construction of TGF-b1 signal-protein-knocked down cell lines and western blot
The procedure for TGF-b1, Smad4, Smad2 and Smad3 gene silencing was described previously. 8, 9, 32 These human TGF-b1 signal protein-specific oligonucleotide sequences were synthesized (Sangon Inc, Shanghai, China) and ligated into the mammalian expression vector, pSUPER gfp-neo (Catalog: VEC-PBS (phosphate-buffered solution)-0006, OligoEngine, Seattle, WA, USA) at the BglII and HindIII cloning sites. A neomycin resistance cassette was cloned into the pSUPER vector and transfected into RMS cell lines using Effectent Transfection Reagent (Qiagen, Hilden, Germany). To test the efficiency of the gene silencing, western blot analysis was utilized to explore the above signal proteins and conventional TGF-b1 target Smad7. Membranes were incubated with specific antibodies against TGF-b1, Smad4, Smad2, Smad3 and Smad7 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) diluted at 1:1000. ENOX2 rabbit polyclonal antibody was purchased from Abcam, Inc (Cambridge, MA, USA), and PAX9 mouse polyclonal antibody was obtained from Abnova Inc (Taipei, Taiwan). Proteins were visualized with peroxidase-conjugated secondary antibodies at 1:2000, using an enhanced chemiluminescence detection system (Santa Cruz).
RNA isolation and miRNA arrays Total RNA was isolated from TGF-b1-knocked down RD, SMS-CTR and RH28, respectively, using TRIzol reagent (Invitrogen, Carlsbad, CA, USA). After having passed RNA quantity measurement using the NanoDrop 1000, the samples were labeled using the miRCURY Hy3/Hy5 Power labeling kit and hybridized on the miRCURY LNA Array (v.16.0) (Exiqon, Vedbaek, Denmark). Following the washing steps, the slides were scanned using the Axon GenePix 4000B microarray scanner. Scanned images were then imported into GenePix Pro 6.0 software (Axon Instruments, Foster City, CA, USA) for grid alignment and data extraction. Expressed data were normalized using the Median normalization. Finally, hierarchical clustering was performed to determine distinguishable miRNA expression profiles among the samples.
Real-time RT-PCR quantification of precursor and mature miRNAs Total RNA was harvested from RMS cell lines and frozen tissues according to the manufacturer's recommendations. Pre-miRNA sequences were obtained from miBase (http://www.mirbase.org/index.shtml). The primers for pre-miRNA were designed with the following criteria: (a) both forward and reverse primers were designed to be located within the hairpin sequence of the miRNA precursors, (b) a maximal extension of four nucleotides in the 5 0 direction was allowed for each primer over the presumed termini of the pre-miRNA, and (c) primers were designed with a maximal T m difference between both primers of p2 1C and a primer length between 18 and 24 nucleotides. The sequences of the miRNA-450b-5p precursor was as follows: 5 0 -GCAGAAUUAU(UUUUGCAAUAUGUUCCUG AAUA)UGUAAUAUAAGUGUA(UUGGGAUCAUUUUGCAUCCAUA)GUUUUGU AU-3 0 . The underlined sequences are forward and reverse PCR primers for miRNA-450b-5p precursors. As the hairpin is contained within both the primiRNA and the pre-miRNA, primers amplify both RNAs. Mature miRNA analysis was performed using the TaqMan miRNA assays, including RT and real-time PCR. The RT reactions were performed using a single miRNAspecific stem-loop RT primer, as described by Chen 33, 34 (for primers, see Supplementary Information, Supplementary Table S2 ).
Northern blot analysis
For quantitative northern blot analysis of miRNAs, 5 mg of total RNA were electrophoresed in a 15% polyacrylamide-urea gel and transferred by electroblotting onto Hybond-N þ membrane (Amersham Biosciences, Piscataway, NJ, USA). Hybridization was performed with 32 P-labeled DNA oligos (see Supplementary Information, Supplementary Table S3 ). Anti-U6, 5 0 -TGTGCTGCCGAAGCGAGCAC-3 0 .
Transient transfection
The sequences of mimics and inhibitors of miRNAs used in our studies are listed in Supplementary Information, Supplementary Table S4 . All of the nucleotides contain 2 0 -OMe modifications at every base and a 3 0 -C3-containing amino linker. 35 To transfect, 100-pmol mimics or inhibitors of miRNA (miR-M or miR-I) and negative control of mimics or inhibitors (MNC or INC) in 200 ml of serum-free medium were mixed with 5 ml of Lipofectamine 2000 transfection reagent (Invitrogen), dissolved in 200 ml of the same medium. The resulting transfection solutions were then added to each well containing 1.6 ml of the medium. Eight hours later, the cultures were replaced with differentiation medium. The specific siRNAs of ENOX2 and PAX9 were designed with BLOCK-iT RNAi Designer (Invitrogen) (ENOX2 siRNA: 5 0 -GGAATTGCCGGACAACCAA-3 0 ; PAX9 siRNA: 5 0 -GCGTGTGC GACAAGTACAA-3 0 ) (synthesized by Shanghai GeneCore Biotechnologies Co, Ltd, Shanghai, China). The siRNA transfection was conducted following identical procedures as for miR at a final concentration of 30 nM.
Immunohistochemistry
Paraffin-embedded tissue sections (3-5 mm thick) were immunostained. After boiling in 10 mM citrate buffer for 10 min in a microwave oven, the tissue sections were incubated with 10% normal rabbit serum in buffer to block nonspecific binding sites, and incubated with antibodies at 4 1C overnight. The slides were incubated with peroxidase-conjugated IgG (Genomics, Shanghai, China) and stained with diaminobenzidinechromogen substrate mixture (DAKO, Carpinteria, CA, USA), and then counterstained with hematoxylin. The expression of proteins were classified according to the following grading system: staining extensity was categorized as 0 (no positive cells), 1 (p25% positive cells), 2 (425% and p50% positive cells ) or 3 (450% positive cells), and staining intensity TGF-b1 suppression of miRNA-450b-5p expression MM Sun et al was categorized as 0 (negative), 1 (weak), 2 (moderate) or 3 (strong). The total immunoreactive score was a summation of the individual categories.
Cell growth assays
The embryonal (RD) and alveolar (RH28) RMS cell lines were plated at 5 Â 10 4 cells per well in 96-well plates, with transfection solutions containing miR-450b-5p-M, miR-450b-5p-I or NC for 8 h. Then, the culture medium was replaced with differentiation medium. The [ For the MTT assay, after the cells were incubated at 37 1C for 4 h to allow MTT formazan formation, the medium and MTT were replaced by 100 ml DMSO to dissolve the formazan crystals. Then, the optical density at 557 nm was determined using a microplate reader (Model 550; Bio-Rad, Hercules, CA, USA). The mean value from triplicate wells for each treatment was determined.
Apoptosis assay and immunofluorescence staining
After cultivating on coverslips for 24 h in Dulbecco's modified Eagle's medium that contained 10% fetal calf serum, the coverslips were placed at the bottom of each well. The 400 ml of the above resulting transfection solutions were then added to each well containing 1.6 ml of medium. Eight hours later, the culture medium was replaced with differentiation medium. After 6 days, coverslips were then washed with iced PBS and fixed with 4% paraformaldehyde for 15 min at 4 1C. Briefly, the treated cells were permeabilized with 0.1% Triton X-100 for fluorescein isothiocyanate (FITC) end-labeling of the fragmented DNA of the apoptotic RD cells, using a TUNEL cell apoptosis detection kit (Beyotime, Shanghai, China). Expression of caspase-3 and MHC was analyzed using rabbit anti-caspase-3 and MHC (Boster, Wuhan, China). At least 200 cells per slide in random fields were counted under a fluorescence microscope (BX2-FLB3-000; Olympus, Tokyo, Japan) to determine the percentage of FITC-positive cells.
Electron microscopy
After RD cells were plated at 5 Â 10 4 cells per well in six-well plates with transfection solution containing miR-450b-5p-M for 6 days, the cells were harvested, fixed with 3% glutaraldehyde and osmium tetroxide, dehydrated and embedded in Epon812. Thin sections were cut at a thickness of 50 nm, stained with uranyl acetate and lead citrate, and examined under an H-600IV electron microscope (Hitachi Inc, Tokyo, Japan).
In vivo tumorigenicity
All animal procedures were approved by the Ethics Review Committee for Animal Experimentation of Soochow University. A total of 100 male BALB/c nude mice (5-6 weeks old and 18 g in weight) were purchased form SLAC Laboratory Animal Co Ltd (Shanghai, China). The mice were divided into six groups of 20 mice each. All mice were injected subcutaneously in the right flank with 100-ml RD cell suspension (1 Â 10 7 ). For intratumoral transfection, 100 pmol mimics or inhibitors of miRNA and negative control oligonucleotides in 100 ml of PBS were mixed with 5 ml of Lipofectamine 2000 transfection reagent (Invitrogen) dissolved in 100 ml of the same PBS. Once tumors reached B0.5 cm 3 , the 200 ml of the above resulting transfection solutions were injected into the tumor once weekly for 4 weeks. Tumor size was measured in a blinded manner weekly with calipers, and tumor volume was calculated. Histological differentiation was evaluated by observing changes in morphology and expression of MyoD markers.
Bioinformatic prediction of miRNA targets
The following bioinformatic algorithms were utilized to predict miRNA target sites: target ccan 6.1 (http://targetscan.org), Diana microT 4.0 (http://diana.cslab.ece.ntua.gr/DianaTools/index.php?r=microtv4/index) and MICRORNA.ORG (http://www.microrna.org/microrna/home.do).
Construction of 3
0 -UTR luciferase plasmid and reporter assays
To create ENOX2-and PAX9-3 0 -UTR luciferase reporter constructs, the fulllength 3 0 -UTR of ENOX2 (1746 nucleotides) and PAX9(1026 nucleotides) was amplified using complementary DNA from RD (primers of ENOX2: forward -5 0 -TGTGTGAGAGTCCAGCCTTG-3 0 , reverse -5 0 -AAGTAAGTTCCGGG GTACATG-3 0 ; primers of PAX9: forward -5 0 -GGTGCTCTCGCAAGGAGAAA GG-3 0 , reverse -5 0 -GCGCTTATGAGTTAAACTGTGTC-3 0 ). The primers were digested and cloned into the Xba1-site of pGL3 (Promega, Madison, WI, USA), checked for orientation, sequenced and named Wt. The miR-450b-5p-binding sites for ENOX2 and PAX9 are indicated in Figure 5 . The mutagenesis within selected seeding sequence regions was conducted according to the following rules: A was changed to T and vice versa. For reporter assays, RD and RH28 were transiently transfected with Wt or mutant reporter plasmid and miR-450b-5p mimic and inhibitor using Lipofectamine 2000 (Invitrogen). Reporter assays were performed 24 h post transfection using the Dual-luciferase assay-system (Promega), and normalized for transfection efficiency by co-transfected Renilla luciferase. The luciferase signal was read using a TD-20/20 Luminometer (Turner Biosystems, Sunnyvale, CA, USA).
Statistical analysis
All data were presented as mean and s.d. Analysis was conducted using SPSS 10.0 (Chicago, IL, USA). Student's unpaired t-test was used to compare values of test and control samples. A value of Po0.05 was considered to indicate a statistically significant result.
